Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: JACC Heart Fail. 2019 Mar;7(3):228–238. doi: 10.1016/j.jchf.2019.01.003

Figure 2a – Kaplan-Meier survival curves for primary outcomes and components according to treatment arm and stratified by sex.

Figure 2a –

There was no significant association between spironolactone and the primary outcome or HF hospitalization in either women or men. Spironolactone was associated with a significantly reduced risk of CV mortality in multivariate analysis, but the interaction between sex and treatment arm was non-significant.